[{"id":"3d78b9c9-76dd-4802-b171-aa3cd7379f4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02290145","created_at":"2021-01-18T10:47:43.754Z","updated_at":"2024-07-02T16:35:28.309Z","phase":"Phase 2","brief_title":"Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage","source_id_and_acronym":"NCT02290145","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 overexpression • CCND1 expression • CCND1-H","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CCND1 expression • CCND1-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • 5-fluorouracil"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-11-22"},{"id":"5344b2f6-be19-468a-abe6-7dd10ed181d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04807881","created_at":"2021-03-19T15:59:16.539Z","updated_at":"2024-07-02T16:35:30.105Z","phase":"Phase 1","brief_title":"Phase Ib Clinical Study of Keynatinib","source_id_and_acronym":"NCT04807881","lead_sponsor":"Medolution Ltd.","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 overexpression • CCND1 expression • CCND1-H","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CCND1 expression • CCND1-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e keynatinib (TL007)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 10/10/2027","primary_completion_date":" 10/10/2027","study_txt":" Completion: 04/10/2028","study_completion_date":" 04/10/2028","last_update_posted":"2023-11-07"}]